NeurAxis, Inc.
AMEX:NRXSBiotechnology
+$0.29 today
- Market cap
- $65.43M
- Beta
- 1.41
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.67
Volume 0.21M
Average 0.18M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
NeurAxis, Inc.
AMEX:NRXS
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +10.0% | +103.3% (3yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +10.0% over three years. Forward estimates point to Revenue at +103.3% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Minerva Neurosciences, Inc. NASDAQ:NERV | $114.62M | $2.30 | Not rated | -0.2 | -49.77% |
Rallybio Corporation NASDAQ:RLYB | $84.64M | $15.72 | Not rated | -11.6 | +205.19% |
Enlivex Therapeutics Ltd. NASDAQ:ENLV | $20.03M | $1.19 | Not rated | 0.0 | -70.98% |
Continue the stock analysis
Jump to another research area for this company.